News summary

NKGen Biotech reports long-term troculeucel observations

Source: Longevity Technology • Published: 17 Nov 2026, 11:31

Summarized by Masters of Longevity from Longevity Technology.

A single moderate Alzheimer’s patient had sustained CDR‑SB score reductions over 24 months.

NKGen Biotech reports long-term troculeucel observations
Key Takeaways
  • A single patient showed CDR‑SB improvement from 11 to 7.
  • CDR‑SB continued improving to 4.5 by month twelve.
  • Scores remained about 4.0–4.5 during the yearlong extension.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.